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Letters to the editor
Evaluation of the leukocyte esterase test (LET) as
pre-screening test to reduce costs for national
population-based Chlamydia trachomatis screening
programs
To the Editor:
With great interest, we read the article by Blake and
colleagues on the re-evaluation and potential re-appreci-
ation of the Leukocyte Esterase Test (LET) as an initial
screening test to be followed by nucleic acid amplifica-
tion testing (NAAT) confirmation [1]. We too have re-
cently evaluated the inexpensive LET as compared with
commercial polymerase chain reaction (PCR) detection
of Chlamydia trachomatis to prescreen urine samples
obtained from an asymptomatic population. Below we
summarize our results and propose evaluation and imple-
mentation tools based on the study of Blake et al [1] and
our own results.
From the previously described PILOT study [2],
which assessed the presence of C. trachomatis DNA by
PCR (Roche Diagnostic System, Basel, Switzerland) in
8383 randomly selected women and men (aged 15–29
years) by using a home-sampling urine kit, we performed
the LET as described by the manufacturer (Roche) simul-
taneously in 2100 of those subjects. In addition, the effect
of longer LET test incubation (two vs. five minutes) was
assessed to potentially identify more C. trachomatis
DNA-positive patients. Finally, the effect of time from
urine sampling until LET testing was determined.
By PCR, 55 subjects (2.6%) were identified as C.
trachomatis DNA positive (all true positives as assessed
by C. trachomatis serovar determination [3]). Using the
LET, we identified 53% of the C. trachomatis DNA-
positive subjects, whereas extended LET incubation
identified 64%. As compared with two-minute incuba-
tion, 16% additional LET positives were identified after
five-minute incubation (41% had identical LET values
for two- and five-minute incubation and 57% had in-
creased LET values after five-minute incubation). From
the C. trachomatis DNA-negative subjects, two-thirds
were LET negative (five-minute incubation). The time
between urine sampling (home obtained) and LET testing
(one to seven days) did not influence the identification of
the number of C. trachomatis DNA-positive subjects.
The 36% C. trachomatis DNA-positive subjects
missed using the above-described approach would be
unacceptably high if the test was used for sexually trans-
mitted infection (STI) diagnostic purposes. However, al-
most 90% of the C. trachomatis infections are asymp-
tomatic, and these people will not seek medical attention
and thus will not be treated in most cases anyhow. The
question then arises whether using an inexpensive test
with, however, a lower sensitivity as compared with
NAAT, would result in health gains in terms of C. tra-
chomatis-positive cases cured and complications averted
that outweigh the screening costs. To answer this ques-
tion, further studies are needed, which have to address
the following:
Cut-off value of LET (use trace [1]) and an extended
incubation period to five minutes.
Include a cost-effectiveness analysis comparing
both LET and NAAT: retesting after prescreen-
ing by LET would reduce the number of expen-
sive PCR tests by two-thirds (associated costs:
EUR 25 for a PCR assay vs. EUR .40 for a LET).
In addition, reduced costs associated with tech-
nician time and disposables will further signifi-
cantly decrease total screening costs if LET is
used as a prescreening test.
Evaluate the use of both LET and nitrites, an ap-
proach forwarded in a recent meta-analysis of
the urine dipstick test [4].
The effect of preselection of the asymptomatic
screening population based on recently de-
scribed selection variables obtained in an over-
10,000-person screening study [5].
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Partner tracing efficiency versus screening only one
gender: in most cases women have been sug-
gested in single-gender screening approaches.
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We read Dr. Morré and colleagues’ letter with interest
and appreciate their suggestion to increase the incubation
period of the leukocyte esterase test (LET) to five minutes
[1]. Now that home urine collection and population screen-
ing are a realistic possibility, it is encouraging to know that
the time between urine sampling (home obtained) and LET
testing did not influence the identification of C. trachomatis
DNA-positive persons.
As we had previously commented [2] and Morré et al
also indicate [1], the LET appears to miss a substantial
proportion of C. trachomatis infections that are detected by
a nucleic acid amplification test (NAAT). As they point out,
the next question becomes, “Are the increased costs asso-
ciated with the more sensitive test outweighed by the costs
averted via detecting more infections?” We have been in-
terested in the same question and have performed a cost-
effectiveness analysis addressing this issue in a population
of males, aged 14 to 18 years, in detention centers [3]. We
found that it is not only cost-effective, but also cost-saving
to screen all asymptomatic males in detention with a NAAT
rather than selectively screening only the LET-positive
males. This finding may be age and population dependent,
however, and more studies are needed to confirm these
conclusions in other groups, such as can be found in na-
tional screening programs.
Our screening strategy in detention not only provides the
opportunity to treat current and recent past partners, but also
may avert infection in future partners, who will not be
exposed to the index male’s infection [3]. As a result, the
additional cost of universal NAAT screening is outweighed
by the cost savings associated with averting additional cases
of pelvic inflammatory disease in female partners. Future
cost-effectiveness studies are required to answer these im-
portant questions of how to best manage population-based
screening programs for Chlamydia trachomatis infections.
Diane R. Blake, M.D.
Celeste A. Lemay, R.N.
University of Massachusetts Medical School
Worcester, Massachusetts
Charlotte A. Gaydos, Dr.P.H.
Thomas C. Quinn, M.D.
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